Latest publications

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

AbstractBackground: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posted by : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : J Natl Cancer Inst

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

AbstractBackground: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...

Posted by : , Dr. Dewi VERNEREY
Journal name : World J Gastrointest Oncol

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractKeywords: Adjuvant; Chemotherapy; Colon cancer; Guidelines; Randomised controlled trials; Time-to-event...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Journal name : Eur J Cancer

01 2020, March

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

AbstractBackground: Despite improvement in colorectal liver metastasis (CLM) treatment, survival after liver...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Surg Oncol

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posted by : Dr. Dewi VERNEREY
Journal name : Clin Colorectal Cancer

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]

AbstractIntroduction: Perioperative chemotherapy is the standard strategy for localized gastric cancers....

Posted by : Dr. Dewi VERNEREY
Journal name : Bull Cancer

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

AbstractBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Oncol .

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Oncologist

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

AbstractBackground: FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Clin Colorectal Cancer

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

AbstractBACKGROUND:Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain...

Posted by : Dr. Dewi VERNEREY,
Journal name : Ann Surg Oncol.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

AbstractBACKGROUND:Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease....

Posted by : Dr. Dewi VERNEREY
Journal name : Br J Cancer

Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.

AbstractBACKGROUND:Despite the critical roles of Th1-polarised CD4+ T cells in cancer immunosurveillance, the...

Posted by : Dr. Dewi VERNEREY
Journal name : Br J Cancer.

Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.

AbstractPURPOSE:Defective mismatch repair system (dMMR) has been shown to have a favorable impact on outcome in patients...

Posted by : Dr. Dewi VERNEREY
Journal name : Int J Radiat Oncol Biol Phys

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

AbstractBACKGROUND:We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with...

Posted by : Dr. Dewi VERNEREY
Journal name : Cancer Epidemiol Biomarkers Prev

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

AbstractIn patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Cancers

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

AbstractBACKGROUND:Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Br J Surg

A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research.

AbstractINTRODUCTION:The demographics of oncology residents has changed since 2010 with the increase in the size of...